Oxcarbazepine NDC 27241-239

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-239Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0239Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-239-01	27241023901	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-239-01)Marketed from Feb 22, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxcarbazepine
Generic name (nonproprietary): oxcarbazepine
Active ingredients: Oxcarbazepine — 600 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217659
Marketing start: Feb 22, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 27241-239_ffbd0c62-0cbd-4ea3-b1a1-1a40a16884e3SPL ID ffbd0c62-0cbd-4ea3-b1a1-1a40a16884e3SPL set ID d947e9b1-2a15-4048-bb4e-fe56b6851848RxCUI 1365653, 1365842, 1365844UNII VZI5B1W380UPC 0327241238017, 0327241239014, 0327241237010
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241023901 followed by a unit qualifier and the quantity

Package 27241-0239-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 30, 2025.

Indications (excerpt from the label)

Oxcarbazepine extended-release tablets are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. Oxcarbazepine extended-release tablets are indicated for the treatment of partial-onset seizures in patients 6 years of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217659

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217659
Product	Strength	Form · route	Labeler	Product NDC
Oxcarbazepine	Oxcarbazepine 150 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-237
Oxcarbazepine	Oxcarbazepine 300 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-238